We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns

By LabMedica International staff writers
Posted on 17 Jun 2025

As the opioid crisis continues to impact communities across the United States, laboratories encounter significant difficulties in accurately detecting opioid substances in individuals with opioid use disorder. More...

Traditional blood testing for opioids typically demands large blood volumes, which are hard to collect from chronic opioid users who often have damaged veins or other medical complications. Meanwhile, urine-based tests frequently yield unreliable results. The issue is even more concerning among pregnant women, with statistics showing that one in five expectant mothers in the U.S. self-reports opioid misuse. This can lead to neonatal abstinence syndrome (NAS), a condition in which newborns experience withdrawal symptoms due to prenatal opioid exposure. Currently, the diagnosis of opioid exposure in infants relies primarily on evaluating symptoms and reviewing the mother's substance use history, as no standard blood-based diagnostic test exists for opioid detection in newborns. Researchers have now introduced new diagnostic methods for identifying opioid compounds in both adults suffering from opioid use disorder and infants affected by NAS.

The new techniques, described in two research studies published by Brown University (Providence, RI, USA), could offer healthcare professionals more effective tools to address opioid-related health conditions. In the first study, featured in Scientific Reports, the researchers describe a rapid method for identifying six different opioid compounds using only a minimal amount of serum, approximately equivalent to a finger prick. The team developed a fully automated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay that can detect opioid compounds from micro-samples such as serum or dried blood spots. The technique demonstrated the ability to precisely quantify six opioids — buprenorphine, methadone, codeine, hydrocodone, morphine, and oxycodone — using just 20 microliters of serum, which is less than a single drop.

The researchers then incorporated this diagnostic approach into an ongoing clinical trial investigating the use of oxytocin alongside opioid agonist therapy. By utilizing the microsampling technique, they were able to detect opioid usage that conventional urine testing had missed. This more refined detection allowed the research team to demonstrate that oxytocin could be an effective adjunct treatment for reducing opioid use in patients with opioid use disorder. Following the success of detecting opioids through small blood samples in adults, the researchers explored further applications. In a second study published in SLAS Technology, they showcased a technique for detecting opioids in dried blood spots, a sample type that is routinely collected from newborns across the country. This breakthrough could enable the first quantitative assessment of opioid exposure in neonates.

The team developed a device designed to extract possible opioid compounds from dried blood spots, which are usually obtained from a newborn’s heel shortly after birth. The device works by applying an electric field to the dried blood spot to extract the target compounds. After this extraction, the sample can be analyzed using mass spectrometry, a technique already commonly used in neonatal screening labs. The findings confirmed that the method could reliably detect various opioid substances such as codeine, hydrocodone, morphine, methadone, and oxycodone. Additionally, the process is fully automated, making it well-suited for clinical implementation, according to the researchers. They believe this advancement could enhance both diagnosis and treatment of NAS. By knowing the exact concentration of opioids present in an infant’s system, clinicians may be able to make more informed decisions about whether medication is required and determine the appropriate dosage. The researchers emphasize that both studies aim to create more accessible, practical, and patient-centered diagnostics, and they hope their findings will lead to real-world applications in the treatment and management of opioid exposure.

“This wasn’t about creating another lab tool,” said Ramisa Fariha, a postdoctoral research associate in molecular biology, cell biology, and biochemistry at Brown, who led the research. “It was about reimagining what’s possible at the point of care. We were responding to a void that was always there, and we wanted to address it.”

Related Links:
Brown University


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.